| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-09-22 | SELLAS Life Sciences (Switzerland) | nomination |
Cancer - Oncology - CNS diseases | Nomination | ||
| 2015-09-21 | Aduro Biotech (USA - CA) | nomination |
Nomination | |||
| 2015-09-21 | Biophytis (France) Patheon (USA - NC) | BIO101 (Stemmacantha carthamoides) | sarcopenic obesity | services contract production manufacturing |
Metabolic diseases | Services contract |
| 2015-09-21 | Regeneron Pharmaceuticals (USA - NY) Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) (USA) | monoclonal antibody therapy for the treatment of Ebola virus infection | Ebola fever | services contract production manufacturing |
Infectious diseases | Services contract |
| 2015-09-20 | CMC Biologics (Denmark - USA) River Vision Development (USA - NY)) | RV001 (teprotumumab) | Grave’s orbitopathy and other indications | manufacturing production
|
Ophtalmological diseases | Production agreement |
| 2015-09-20 | CMC Biologics (Denmark - USA) Oncosynergy (USA-France) | OS2966 | Ebola fever | production manufacturing |
Infectious diseases | Production agreement |
| 2015-09-20 | Allergan (Ireland) Apricus Biosciences (USA - CA) | Vitaros™ | erectile dysfunction | licensing |
Men's health | Licensing agreement |
| 2015-09-19 | Amgen (USA - CA) Merck&Co (USA - NJ) | talimogene laherparepvec and Keytruda® (pembrolizumab) | recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-09-19 | Arsanis (USA - MA) | nomination |
Infectious diseases | Nomination | ||
| 2015-09-18 | Selvita (Poland) | establishment of a new subsidiary in the US |
Establishment of a new subsidiary in the US | |||
| 2015-09-18 | Momenta Pharmaceuticals (USA - MA) | nomination |
Nomination | |||
| 2015-09-18 | Aegerion Pharmaceuticals (USA - MA) | Rare diseases | Nomination | |||
| 2015-09-18 | Bayer (Germany) | restructuration |
Restructuring | |||
| 2015-09-17 | CEVEC Pharmaceuticals (Germany) Genethon (France) | lentivirus packaging cell lines based on CEVEC’s proprietary CAP®GT technology | licensing collaboration |
Rare diseases - Technology - Services | Licensing agreement | |
| 2015-09-17 | Sandoz (Switzerland) | BioInject (biopharmaceutical manufacturing facility in Austria) | opening of new premises |
Opening of new premises | ||
| 2015-09-17 | Osiris Therapeutics (USA - MD) | nomination |
Nomination | |||
| 2015-09-16 | Amgen (USA - CA) Xencor (USA - CA) | bispecific antibodies | R&D licensing development commercialisation |
Cancer - Oncology - Inflammatory diseases | Licensing agreement | |
| 2015-09-16 | Oncobiologics (USA - NJ) | nomination |
Nomination | |||
| 2015-09-16 | Medivir (Sweden) | nomination restructuring |
Cancer - Oncology - Infectious diseases | Nomination | ||
| 2015-09-16 | Avexis (USA - IL) | nomination |
Rare diseases - Genetic diseases - Neurological diseases | Nomination |
